GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: Ricamycin® | TMS-19-Q
                                 
                                                         
                            
                            
                            
                                 
                                
                                rokitamycin is an approved drug 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Rokitamycin is a 16-membered semisynthetic macrolide antibacterial compound [3].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| Rokitamycin received Japanese PMDA approval in 1986, followed by introduction into clinical use in Italy, Russia, China and a number of South American countries [1], but we have been unable to find reliable evidence that supports current clinical use of this drug. |